Anti‐angiogenic drugs, such as bevacizumab and sorafenib, have been demonstrated to starve the tumour by inhibiting blood vessel formation via inhibition of VEGF and tyrosine kinase signalling, respectively [9, 10]. The gene discussed is VEGFA; the disease is neoplasm.